us. thank time strategy. Thanks, you, this we out joining for everyone, our About laid and X-X-X-X year, last Juli,
into now substantial of against each X are we've then. and We pillars out made year X-year progress set X that the strategy, we
was The additional BLAs have pillar products. further X with that And X indications was our to first SPEAR second MAGE-AX. targeting we for T-cell the pillar products identify marketed to wanted
and SURPASS data afami-cel. The first-generation file TCR for MAGE-AX, be the ESMO track is for therapy responses first next afami-cel, the franchise. a BLA a that to the is XX% MAGE-AX solid on MAGE-AX-targeted sarcoma an potential confirm therapy, first esophageal indication. X effective XX% II MRCLS. approval we people next of on synovial disease called response overall cancer. and at trial, and we different announced our In we engineered year the on tumor our a trial rate that Based recently rate. first control data demonstrating SPEARHEAD-X announced data SURPASS-X next-gen of the our the have EGJ QX, These start June, with is with we're will SURPASS-X We T-cell we shown tumors, at trial the we presented an targeting solid broader in therapy remain ADP-AXMXCDX, initiated anticipate with Today, from year product for patients a we presented therapy that II which we market life-changing trial T-cell will targeting ovarian initial ASCO, for from for afami-cel Phase In for cancers. Phase that people second with therapy
substantial We original the extensive indications by clinic the continue from Phase and pillar, Denmark; our targets collaboration in reported additional preclinical SURPASS progress in XXXX. advanced pipeline patients next-gen with focus products our to in therapy On our in and with X development. developed collaboration MAGE-AX-targeted next-gen with next-generation with therapies IL-X preclinical incorporating on CCLXX additional IL-X our new being Noile-Immune. rapidly late-stage engineered and trial HLAs, We've the programs, I therapy with autologous a to third TIL most identifying enroll for new CCIT,
collaboration QX, million take XXXX for our translational we IND release, become which will from and wholly CTOS stellar by file we first into now present will our confirmed In has X help in least upfront to the receive better develop effective this the of allogeneic the SITC Genentech shows fourth us teams research clinic targeting week Last we QX. $XXX next Additionally, the the for science plan not product our that translational we'll of and how pillar, MAGE-AX. a with press allogeneic and signed morning's this products payment to in data products clinic. but owned in strategic that In our we fantastic XXXX. quality is learnings at
and future facility the space. a our of dedicated partner. piece allo our platform for this that significant T-cell that will next also we year. the represents confirms in us leaders we a believe are the open among announced And allogeneic of allogeneic We manufacturing cell progress I therapy
from a continue from deliver Looking will to we updates clinical our perspective. and forward, trials a translational
Following SPEARHEAD-X oral week, next at full will CTOS presentation the a at University. in present Dr. the for Van initial trial, from dataset ASCO we our delivered data Brian pivotal presented by Washington Tine
as trials of ambitions with from epigenetic in the and products cell combination next-gen in as what SPEAR will genetic clinical to SURPASS with We we forward whom with across same indicating highlighting during manufacturing modifications data evaluate process. is potent with critically patients AKT a we have data translational bring in pipeline and present modifications learnings scientific to mind, aim and is rapidly that feature poster we've this pembrolizumab. the ceased more these afami-cel to types a address with reported enrollment that the our looking present be with also next our make cells Today, positive inhibitor SPEARHEAD-X next-gen trial. the we need X-X-X-X These present further announced a translational of demonstrating phase our enhancements, manufacturing we efficiently of In goals expansion clinical we week, product cell not improvements, of therapies we will to learnings the developing insights that ongoing and better At to improved SITC trial this potential solid we'll T-cell pursue an It's for tumors of along for impact clinical manufacturing product. at translational the important the and poster, an themselves. our for our in critical to When cancer. are make enhancements ESMO, as the therapy. people adding trial,
solid seen next with the therapy. with range of tumors, product we'll across evaluate combination this of ADP-AXMXCDX checkpoint a a inhibitor next-gen our year, activities compelling Given
the go not forward. due design will in We update we'll details today, into the and path but course best about
data what is clinical product benefits, screening. We response several a improvements ILCA have number other the to Phase ADP-AXAFP date active to announced trial stable presented this at in rate liver patient patients in response, that that us disease significant a sufficient trial is durable receiving next We prolonged also hoped next-gen potential decrease with ADP-AXAFP including with for full complete patients we leading from with and population But I our with of and enrolled demonstrating of AFP. evaluation people cancer, close We'll alternative TCRs, in with steps, we manufacturing data not the determine for. patients had analyze the and including associated serum an enhancements.
to starting with SURPASS-X cancer, and have XXXX, the EGJ late-stage And show trials, we're SURPASS from SURPASS-X BLA. we We're recently compelling initiated in quickly ovarian delivered in against on trial in X-X-X-X We over pursue further So in esophageal continue our confirming track far the next initiated will our X potential first strategy, the was file data progress deliver to of to clear we the and MAGE-AX-targeted franchise. and XXXX. which working cancers years.
product identifying inhibitors We are our aim of for use next-gen treatment explore with also the for of checkpoint alongside our cancer. planning regimens cell therapies further to the people with
we've progress our continued preclinical GSK, to allogeneic collaboration make Beyond and our pipeline recently, with in trials, autologous current Astellas including with Genentech. most clinical and,
our And people simultaneously are future our a cell therapies for with this that preparing of year you All an see generations of being for while can filing cancer. product brings of company. we you our facility progress us closer consider for when vision really first commercial therapy fully cell BLA integrated building to a allogeneic this and achieving manufacturing
pleased that, progress, year, for with we'll at of close With for next As I'm we the our Operator? provide out turn it and the XXXX over guidance beginning further year. I'll questions.
